AI giants lean into health care to stall public backlash
AI has an image problem . And one way to fix it is for top companies to dive headlong into health care. Why it matters: Saving the world with AI-designed cures is better than being blamed for ruining the environment or driving up Americans' utility bills. But even the most advanced AI models can't produce miracle treatments at the moment — and could create serious security risks if they try. That…
AI companies are increasingly turning to the healthcare sector in an attempt to alleviate concerns about public backlash. By focusing on medical advancements, these tech giants aim to reshape public sentiment rather than facing criticism for environmental damage or soaring utility bills. However, achieving breakthrough treatments remains a distant goal, and there are worries about potential security risks associated with the deployment of advanced AI models.
Anthropic, for instance, is investing heavily in health care and biology ahead of its anticipated initial public offering. CEO Dario Amodei expressed optimism about the company's potential to generate significant results in the coming years. Similar moves can be seen at Nvidia and Eli Lilly, who are collaborating on a $1 billion drug discovery lab in San Francisco, merging life science researchers with AI model builders and engineers.
On the other hand, researchers like Isomorphic Labs, a Google spinoff, have raised $2.1 billion to bolster their AI and clinical teams, in partnership with pharmaceutical giants such as Novartis, Lilly, and Johnson & Johnson. Despite these efforts, breakthroughs may still be years away, raising concerns among an increasingly anxious U.S. public who are wary of data centers and the potential job displacement brought about by AI.
AI is already accelerating drug development and aiding in medical imaging and diagnosis, but it has also led to increased costs within the healthcare industry, primarily due to software and electronic documentation. Moreover, there are apprehensions about the misuse of AI-enabled research tools, such as the potential creation of biological weapons.
AI companies are investing in healthcare as they prepare to go public, aiming to diversify their revenue streams and address the public's perception of AI as an environmental and security risk. However, significant hurdles remain, including strained relations with the Trump administration, which seeks a hands-off regulatory approach while maintaining oversight of safety and privacy concerns.
Additionally, public opinion remains skeptical of big drug companies due to concerns over high drug prices, which could lead to backlash against AI companies if they are perceived as prioritizing profits over patient care. Ultimately, AI labs will need to demonstrate tangible societal benefits to ensure public support, a challenge that hinges on the delivery of real medical advancements.
Written by urgent.news from Axios's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
